Skip to main content

Table 1 Summary of clinical information of all cases harboring 13q12.2 focal amplification

From: Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer

Patient ID Disease stage (TC) Disease stage (PC) Location cM (TC) cM (PC) TBC (months) Detection*
C74 IV B IV B Rectum M1 M1 22.8 Yes
C79 NA NA NA NA NA NA No
C95 II A IV B Left flexure M0 M1 43.4 NA
C109 III B IV B Rectum M0 M1 101.7 Yes
C110 IV A IV B Colon ascending M1 M1 0.7 NA
C118 IV B IV B Colon sigmoid M0 M1 22.9 No
C112 III A IV B Rectum NA NA 27.1 NA
C123 III B IV B Colon sigmoid M0 M1 76.5 Yes
C129 I IV B Colon sigmoid M0 M1 121.3 NA
C166 IV A IV A Colon transverse M1 M1 0.7 No
C178 III C IV B Cecum M0 M1 5.4 Yes
C206 III B III B Rectum M0 M0 7.6 No
C240 III B IV B Colon sigmoid M0 M1 79.9 No
C216+ NA IV B NA NA NA NA NA
  1. The age range of the 14 patients was 45–81 years (mean = 60.7 years, median = 51 years), 36% were female, and 64% were male. TC tissue collection, PC plasma collection, TBC time to first blood collection after diagnosis
  2. *13q12.2 SCNA found in primary tissue; +13q12.2 SCNA was not detected in the first blood draw in patient C216